ReviewTrends in biotechnology2011
Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines.
Review in Trends in biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 174 citations in OpenAlex.
- Bacterial-based cancer therapy: mechanisms and therapeutic advances.Molecular biomedicine · 2026Review
- Bacterialized tumor cells as vaccine.EMBO molecular medicine · 2026Article
- Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Remodeling the Inflammatory Microenvironment: Nanomaterial-Based Targeted Strategies for Systemic Lupus Erythematosus and Lupus Nephritis.Small science · 2026Review
- Passivation-Engineered Zinc Peroxide Nanoparticles as Th1-Biased Adjuvant for Antitumor Immunity.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Intra-tumoral bacteria in head and neck cancer: holistic integrative insight.Cancer biology & medicine · 2025Review
- Article
- Article
- Harnessing outer membrane vesicles derived fromFrontiers in immunology · 2025Article
- Combined ε-Toxin Nanovaccine with Enhanced Immunity for Effective Protection in a Murine Model.International journal of nanomedicine · 2025Article
- Recent advances in bacterial outer membrane vesicles: Effects on the immune system, mechanisms and their usage for tumor treatment.Journal of pharmaceutical analysis · 2024Review
- Cold and hot tumors: from molecular mechanisms to targeted therapy.Signal transduction and targeted therapy · 2024Review
- The emerging tumor microbe microenvironment: From delineation to multidisciplinary approach-based interventions.Acta pharmaceutica Sinica. B · 2024Review
- Muscularis macrophages controlled by NLRP3 maintain the homeostasis of excitatory neurons.International journal of biological sciences · 2024Article
- Immunomodulatory Plant Natural Products as Therapeutics against Inflammatory Skin Diseases.Current topics in medicinal chemistry · 2024Review
- A Glance on Nanovaccine: A Potential Approach for Disease Prevention.Current pharmaceutical biotechnology · 2024Review
- Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles.Biopolymers · 2023Review
- Microbe-host interactions: structure and functions of Gram-negative bacterial membrane vesicles.Frontiers in microbiology · 2023Review
- Protective efficacy ofFrontiers in cellular and infection microbiology · 2023Article
- Antimicrobial Peptides Therapy: An Emerging Alternative for Treating Drug-Resistant Bacteria.The Yale journal of biology and medicine · 2022Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Vaccine development has progressed significantly and has moved from whole microorganisms to subunit vaccines that contain only their antigenic proteins. Subunit vaccines are often less immunogenic than whole pathogens; therefore, adjuvants must amplify the immune response, ideally establishing both innate and adaptive immunity. Incorporation of antigens into biomaterials, such as liposomes and polymers, can achieve a desired vaccine response. The physical properties of these platforms can be easily manipulated, thus allowing for controlled delivery of immunostimulatory factors and presentation of pathogen-associated molecular patterns (PAMPs) that are targeted to specific immune cells. Targeting antigen to immune cells via PAMP-modified biomaterials is a new strategy to control the subsequent development of immunity and, in turn, effective vaccination. Here, we review the recent advances in both immunology and biomaterial engineering that have brought particulate-based vaccines to reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.